357 related articles for article (PubMed ID: 37794448)
1. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy.
Zhao Y; Gan L; Ke D; Chen Q; Fu Y
J Transl Med; 2023 Oct; 21(1):693. PubMed ID: 37794448
[TBL] [Abstract][Full Text] [Related]
2. mRNA as novel technology for passive immunotherapy.
Schlake T; Thess A; Thran M; Jordan I
Cell Mol Life Sci; 2019 Jan; 76(2):301-328. PubMed ID: 30334070
[TBL] [Abstract][Full Text] [Related]
3. [Advances in research of bispecific antibodies for antivirus therapy].
Zhai G; Lu L; Lu H; Chen D
Sheng Wu Gong Cheng Xue Bao; 2019 Jul; 35(7):1174-1183. PubMed ID: 31328474
[TBL] [Abstract][Full Text] [Related]
4. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
[TBL] [Abstract][Full Text] [Related]
5. Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery.
Wu L; Wang W; Tian J; Qi C; Cai Z; Yan W; Xuan S; Shang A
Bioengineered; 2021 Dec; 12(2):12383-12393. PubMed ID: 34895063
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibodies for viral immunotherapy.
Nyakatura EK; Soare AY; Lai JR
Hum Vaccin Immunother; 2017 Apr; 13(4):836-842. PubMed ID: 27786606
[TBL] [Abstract][Full Text] [Related]
7. New approaches to antibody therapy.
Weiner LM; Adams GP
Oncogene; 2000 Dec; 19(53):6144-51. PubMed ID: 11156528
[TBL] [Abstract][Full Text] [Related]
8. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
9. Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller D; Kontermann RE
Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibodies for cancer immunotherapy: Current perspectives.
Müller D; Kontermann RE
BioDrugs; 2010 Apr; 24(2):89-98. PubMed ID: 20199124
[TBL] [Abstract][Full Text] [Related]
11. Bispecific Antibodies: From Research to Clinical Application.
Ma J; Mo Y; Tang M; Shen J; Qi Y; Zhao W; Huang Y; Xu Y; Qian C
Front Immunol; 2021; 12():626616. PubMed ID: 34025638
[TBL] [Abstract][Full Text] [Related]
12. mRNA-based therapies: Preclinical and clinical applications.
Qureischi M; Mohr J; Arellano-Viera E; Knudsen SE; Vohidov F; Garitano-Trojaola A
Int Rev Cell Mol Biol; 2022; 372():1-54. PubMed ID: 36064262
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibodies for cancer therapy.
Hollander N
Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
[TBL] [Abstract][Full Text] [Related]
14. Current perspectives of bispecific antibody-based immunotherapy.
Talac R; Nelson H
J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049
[TBL] [Abstract][Full Text] [Related]
15. Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1.
Li S; Qiao Y; Jiang S; Wang B; Kong W; Shan Y
J Control Release; 2021 Oct; 338():633-643. PubMed ID: 34509584
[TBL] [Abstract][Full Text] [Related]
16. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
Yang F; Wen W; Qin W
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020
[TBL] [Abstract][Full Text] [Related]
17. Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go.
Shivarov V; Blazhev G
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):81-85. PubMed ID: 33900820
[TBL] [Abstract][Full Text] [Related]
18. Recombinant bispecific antibodies for cancer therapy.
Kontermann RE
Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
[TBL] [Abstract][Full Text] [Related]
19. Lipid Nanoparticle Delivery System for mRNA Encoding B7H3-redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors.
Huang C; Duan X; Wang J; Tian Q; Ren Y; Chen K; Zhang Z; Li Y; Feng Y; Zhong K; Wang Y; Zhou L; Guo G; Song X; Tong A
Adv Sci (Weinh); 2023 Jan; 10(3):e2205532. PubMed ID: 36403209
[TBL] [Abstract][Full Text] [Related]
20. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
